Loss of Cyclin B1 followed by downregulation of Cyclin A/Cdk2, apoptosis and antiproliferation in Hela cell line

Xian He Xie, Hee Jung An, Suki Kang, Sunghui Hong, Yoon Pyo Choi, YoungTae Kim, Youngdeuk Choi, Namhoon Cho

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Recent studies have shown that Cyclin B1 is overexpressed in various tumor types but present at low levels in normal tissues. To explore the possibility of employing Cyclin B1 as an anticancer target, we knocked down Cyclin B1 in an HeLa cell line using RNA interference (RNAi). Subsequently, we monitored cell cycle-related molecules by Western blot together with immunofluorescence and determined cell cycle distribution by flow cytometry. XTT and soft agar colony growth experiments were performed to detect cell viability and proliferation. Furthermore, we analyzed cell apoptosis by measuring Bcl-2 and Bax protein level and DNA-ladder assay. After performing Cyclin B1 RNAi, Cyclin B1, Cyclin A and Cdk2 protein levels were found to be markedly downregulated, whereas Cdc2 was almost unaffected; S-phase fraction increased significantly; HeLa cell viability and cell colony forming ability were markedly diminished after the RNAi; Bcl-2 was noticeably attenuated but Bax was hardly changed; and HeLa cells displayed typical DNA ladder. The loss of Cyclin B1 resulted in the downregulation of Cyclin A and Cdk2, S-phase delay and eventually led to cell apoptosis and the decrease of cell viability and proliferation. Our studies suggest that Cyclin B1 may be a promising anticancer target.

Original languageEnglish
Pages (from-to)520-525
Number of pages6
JournalInternational Journal of Cancer
Volume116
Issue number4
DOIs
Publication statusPublished - 2005 Sep 10

Fingerprint

Cyclin B1
Cyclin A
HeLa Cells
Down-Regulation
Apoptosis
Cell Line
RNA Interference
Cell Survival
S Phase
Cell Cycle
Cell Proliferation
bcl-2-Associated X Protein
DNA
Agar
Fluorescent Antibody Technique
Flow Cytometry
Western Blotting
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{5386cef33fe64cc190e474c26eb4c047,
title = "Loss of Cyclin B1 followed by downregulation of Cyclin A/Cdk2, apoptosis and antiproliferation in Hela cell line",
abstract = "Recent studies have shown that Cyclin B1 is overexpressed in various tumor types but present at low levels in normal tissues. To explore the possibility of employing Cyclin B1 as an anticancer target, we knocked down Cyclin B1 in an HeLa cell line using RNA interference (RNAi). Subsequently, we monitored cell cycle-related molecules by Western blot together with immunofluorescence and determined cell cycle distribution by flow cytometry. XTT and soft agar colony growth experiments were performed to detect cell viability and proliferation. Furthermore, we analyzed cell apoptosis by measuring Bcl-2 and Bax protein level and DNA-ladder assay. After performing Cyclin B1 RNAi, Cyclin B1, Cyclin A and Cdk2 protein levels were found to be markedly downregulated, whereas Cdc2 was almost unaffected; S-phase fraction increased significantly; HeLa cell viability and cell colony forming ability were markedly diminished after the RNAi; Bcl-2 was noticeably attenuated but Bax was hardly changed; and HeLa cells displayed typical DNA ladder. The loss of Cyclin B1 resulted in the downregulation of Cyclin A and Cdk2, S-phase delay and eventually led to cell apoptosis and the decrease of cell viability and proliferation. Our studies suggest that Cyclin B1 may be a promising anticancer target.",
author = "Xie, {Xian He} and An, {Hee Jung} and Suki Kang and Sunghui Hong and Choi, {Yoon Pyo} and YoungTae Kim and Youngdeuk Choi and Namhoon Cho",
year = "2005",
month = "9",
day = "10",
doi = "10.1002/ijc.21056",
language = "English",
volume = "116",
pages = "520--525",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Loss of Cyclin B1 followed by downregulation of Cyclin A/Cdk2, apoptosis and antiproliferation in Hela cell line. / Xie, Xian He; An, Hee Jung; Kang, Suki; Hong, Sunghui; Choi, Yoon Pyo; Kim, YoungTae; Choi, Youngdeuk; Cho, Namhoon.

In: International Journal of Cancer, Vol. 116, No. 4, 10.09.2005, p. 520-525.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Loss of Cyclin B1 followed by downregulation of Cyclin A/Cdk2, apoptosis and antiproliferation in Hela cell line

AU - Xie, Xian He

AU - An, Hee Jung

AU - Kang, Suki

AU - Hong, Sunghui

AU - Choi, Yoon Pyo

AU - Kim, YoungTae

AU - Choi, Youngdeuk

AU - Cho, Namhoon

PY - 2005/9/10

Y1 - 2005/9/10

N2 - Recent studies have shown that Cyclin B1 is overexpressed in various tumor types but present at low levels in normal tissues. To explore the possibility of employing Cyclin B1 as an anticancer target, we knocked down Cyclin B1 in an HeLa cell line using RNA interference (RNAi). Subsequently, we monitored cell cycle-related molecules by Western blot together with immunofluorescence and determined cell cycle distribution by flow cytometry. XTT and soft agar colony growth experiments were performed to detect cell viability and proliferation. Furthermore, we analyzed cell apoptosis by measuring Bcl-2 and Bax protein level and DNA-ladder assay. After performing Cyclin B1 RNAi, Cyclin B1, Cyclin A and Cdk2 protein levels were found to be markedly downregulated, whereas Cdc2 was almost unaffected; S-phase fraction increased significantly; HeLa cell viability and cell colony forming ability were markedly diminished after the RNAi; Bcl-2 was noticeably attenuated but Bax was hardly changed; and HeLa cells displayed typical DNA ladder. The loss of Cyclin B1 resulted in the downregulation of Cyclin A and Cdk2, S-phase delay and eventually led to cell apoptosis and the decrease of cell viability and proliferation. Our studies suggest that Cyclin B1 may be a promising anticancer target.

AB - Recent studies have shown that Cyclin B1 is overexpressed in various tumor types but present at low levels in normal tissues. To explore the possibility of employing Cyclin B1 as an anticancer target, we knocked down Cyclin B1 in an HeLa cell line using RNA interference (RNAi). Subsequently, we monitored cell cycle-related molecules by Western blot together with immunofluorescence and determined cell cycle distribution by flow cytometry. XTT and soft agar colony growth experiments were performed to detect cell viability and proliferation. Furthermore, we analyzed cell apoptosis by measuring Bcl-2 and Bax protein level and DNA-ladder assay. After performing Cyclin B1 RNAi, Cyclin B1, Cyclin A and Cdk2 protein levels were found to be markedly downregulated, whereas Cdc2 was almost unaffected; S-phase fraction increased significantly; HeLa cell viability and cell colony forming ability were markedly diminished after the RNAi; Bcl-2 was noticeably attenuated but Bax was hardly changed; and HeLa cells displayed typical DNA ladder. The loss of Cyclin B1 resulted in the downregulation of Cyclin A and Cdk2, S-phase delay and eventually led to cell apoptosis and the decrease of cell viability and proliferation. Our studies suggest that Cyclin B1 may be a promising anticancer target.

UR - http://www.scopus.com/inward/record.url?scp=23244457592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23244457592&partnerID=8YFLogxK

U2 - 10.1002/ijc.21056

DO - 10.1002/ijc.21056

M3 - Article

C2 - 15818617

AN - SCOPUS:23244457592

VL - 116

SP - 520

EP - 525

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -